Related Experiment Video
Updated: Jan 8, 2026
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.6K
Are ultrasensitive ctDNA assays ready for clinical use in early-stage NSCLC?
Sam Khan1, Janice J N Li2, Natasha B Leighl2
1Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Leicester Cancer Research Centre, University of Leicester, Leicester, Leicestershire, UK.
Cell
|December 12, 2025
Abstract:
Disease recurrence in early-stage non-small cell lung cancer (NSCLC) remains a persistent clinical challenge, underscoring the need for better prognostic biomarkers. In this preview, we highlight the clinical implications of ultrasensitive ctDNA monitoring in lung cancer risk modeling reported by Black et al. in this issue of Cell.
